Axogen Reports Strong Q3 2025 Results, Raises Guidance

AxoGen ( (AXGN) ) has released its Q3 earnings. Here is a breakdown of the information AxoGen presented to its investors.

Axogen, Inc. is a leading company in the development and commercialization of technologies for peripheral nerve regeneration and repair, providing innovative solutions to restore nerve function and improve quality of life for patients with peripheral nerve injuries. In its third-quarter 2025 earnings report, Axogen announced a significant revenue increase of 23.5% compared to the same period in 2024, reaching $60.1 million. The company also reported a net income of $0.7 million, marking a turnaround from a net loss in the previous year. Axogen’s gross margin improved to 76.6%, and adjusted EBITDA rose to $9.2 million, reflecting strong operational performance. Key highlights include the recognition of nerve allografts as a standard medical practice by major surgical societies and expanded insurance coverage, which now includes 18.1 million additional lives. The FDA’s anticipated approval of the Avance Nerve Graft BLA in December 2025 is expected to further bolster the company’s market position. Looking ahead, Axogen has raised its full-year revenue guidance to at least 19% growth, or $222.8 million, and expects to maintain a gross margin between 73% and 75%, despite one-time costs associated with regulatory approvals. The company remains optimistic about its growth trajectory and its mission to establish peripheral nerve repair as a standard of care.